| Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015 | 8998 | 2015 |
| Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA MC Liu, GR Oxnard, EA Klein, C Swanton, MV Seiden, MC Liu, ... Annals of Oncology 31 (6), 745-759, 2020 | 1045 | 2020 |
| Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials … L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ... Journal of clinical oncology 35 (35), 3924-3933, 2017 | 882 | 2017 |
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J Rinehart, AA Adjei, PM LoRusso, D Waterhouse, JR Hecht, RB Natale, ... Journal of clinical oncology 22 (22), 4456-4462, 2004 | 733 | 2004 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 670 | 2020 |
| Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non–small-cell lung cancer PM Fidias, SR Dakhil, AP Lyss, DM Loesch, DM Waterhouse, JL Bromund, ... Journal of Clinical Oncology 27 (4), 591-598, 2009 | 591 | 2009 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 555 | 2018 |
| Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ... Annals of oncology 29 (4), 959-965, 2018 | 465 | 2018 |
| Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer H Borghaei, S Gettinger, EE Vokes, LQM Chow, MA Burgio, ... Journal of Clinical Oncology 39 (7), 723-733, 2021 | 448 | 2021 |
| Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. DM Waterhouse, KA Calzone, C Mele, DE Brenner Journal of Clinical Oncology 11 (6), 1189-1197, 1993 | 419 | 1993 |
| Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT … TM Beer, CW Ryan, PM Venner, DP Petrylak, GS Chatta, JD Ruether, ... Journal of Clinical Oncology 25 (6), 669-674, 2007 | 377 | 2007 |
| Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer CP Belani, JS Lee, MA Socinski, F Robert, D Waterhouse, K Rowland, ... Annals of oncology 16 (7), 1069-1075, 2005 | 322 | 2005 |
| Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer HI Scher, X Jia, K Chi, R De Wit, WR Berry, P Albers, B Henick, ... Journal of Clinical Oncology 29 (16), 2191-2198, 2011 | 285 | 2011 |
| Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial DR Spigel, PM Townley, DM Waterhouse, L Fang, I Adiguzel, JE Huang, ... Journal of clinical oncology 29 (16), 2215-2222, 2011 | 260 | 2011 |
| Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma JD Hainsworth, DR Spigel, HA Burris III, D Waterhouse, BL Clark, R Whorf Journal of clinical oncology 28 (13), 2131-2136, 2010 | 224 | 2010 |
| Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75 NM Hahn, WM Stadler, RT Zon, D Waterhouse, J Picus, S Nattam, ... Journal of Clinical Oncology 29 (12), 1525-1530, 2011 | 220 | 2011 |
| Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation—positive advanced non … DR Spigel, C Reynolds, D Waterhouse, EB Garon, J Chandler, S Babu, ... Journal of Thoracic Oncology 13 (5), 682-688, 2018 | 210 | 2018 |
| Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey DM Waterhouse, RD Harvey, P Hurley, LA Levit, ES Kim, HD Klepin, ... JCO Oncology Practice 16 (7), 417-421, 2020 | 206 | 2020 |
| Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial AJ de Langen, ML Johnson, J Mazieres, AMC Dingemans, G Mountzios, ... The Lancet 401 (10378), 733-746, 2023 | 204 | 2023 |
| Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non–small-cell lung cancer DR Spigel, HA Burris III, FA Greco, DL Shipley, EK Friedman, ... Journal of clinical oncology 29 (18), 2582-2589, 2011 | 181 | 2011 |
